RecruitingPHASE1, PHASE2NCT05878860
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Studying X-linked retinoschisis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Atsena Therapeutics Inc.
- Intervention
- ATSN-201(biological)
- Enrollment
- 21 target
- Eligibility
- 6 years · MALE
- Timeline
- 2023 – 2029
Study locations (4)
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- Bascom Palmer Eye Institute, Miami, Florida, United States
- Oregon Health Sciences University, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05878860 on ClinicalTrials.govOther trials for X-linked retinoschisis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06289452Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked RetinoschisisInnoVec Biotherapeutics Inc.
- RECRUITINGEARLY PHASE1NCT06345898Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)West China Hospital
- RECRUITINGNANCT05814952Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine